Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30758612 | 1.00 | KMT2A (0.58) | KMT2AMEN1POLBCYP3A4NFKB1 | |
| SCHEMBL11608927 | 0.85 | RECQL (0.50) | KMT2AMEN1POLBRECQLGAA | |
| SCHEMBL11561782 | 0.85 | CES1 (0.53) | KMT2AMEN1CYP3A4PGRRECQL | |
| SCHEMBL3819605 | 0.83 | MEN1 (0.51) | KMT2AMEN1PGRNR1H2 | |
| SCHEMBL2549717 | 0.83 | MEN1 (0.73) | KMT2AMEN1POLBCYP3A4NFKB1 | |
| SCHEMBL29168855 | 0.81 | KMT2A (0.62) | KMT2AMEN1POLBNR1H3NR1H2 | |
| SCHEMBL30758617 | 0.81 | KMT2A (0.62) | KMT2AMEN1POLBNR1H3NR1H2 | |
| SCHEMBL30758582 | 0.81 | KMT2A (0.62) | KMT2AMEN1POLBCYP3A4NFKB1 | |
| SCHEMBL29168847 | 0.81 | KMT2A (0.62) | KMT2AMEN1POLBCYP3A4NFKB1 | |
| SCHEMBL2890089 | 0.80 | KMT2A (0.60) | KMT2AMEN1POLBCYP3A4NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466799-A | Preparation method of N-substituted phthalimide compound | 西北师范大学 | 2024-01-30 | — | — | CN | disclosed |
| EP-1847532-B1 | IGF-1R INHIBITOR | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-7605272-B2 | IGF-1R inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-10-20 | — | — | US | disclosed |
| US-7605272-B2 | IGF-1R inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090054508-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090054508-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1847532-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054508-A1 | IGF-1R INHIBITOR | IGF1R, IGFBP5, IGFBP1 | KMT2A 1924/4885MEN1 1830/4885POLB 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.